Designed to be Different.
TPX-0131 inhibits Anaplastic Lymphoma Kinase (ALK). Rearrangements of ALK can lead to cancer growth and proliferation. Multiple FDA-approved ALK inhibitors are available to patients for the treatment of ALK+ NSCLC, yet none are active against a broad spectrum of resistant mutations (i.e., solvent front, gatekeeper and compound).
ALK-driven tumors are estimated to represent 3-5% percent of driver oncogenes in NSCLC, and of patients who develop a resistance mutation, G1202R has been reported in approximately 42 percent of NSCLC patients.